肾癌CT引导冷冻消融:辐射负担及手术与随访成像相关的二次癌症风险
该研究基于149例在本机构接受经皮冷冻消融(PCA)治疗小肾肿块(SRM)的患者,按CT剂量报告计算手术及随访CT的有效剂量,并依据多学科专家组的随访建议估算最小与优选随访方案(5年 vs 10年)的累积剂量及基于BEIR VII报告的终生归因癌症风险。结果显示最小与优选方案总剂量分别为174与294 mSv,随访CT占总剂量的大部分(89% vs 94%),CT透视仅占很小部分(1.8% vs 1.1%);70岁男性完成优选随访方案的终生归因癌症风险为0.8%(1/131),30岁女性为3.4%(1/29)。
要点
- 随访CT是PCA术后辐射剂量的主要来源,最小与优选方案中分别占总剂量的89%与94%。
- CT透视在最小与优选方案中仅占总辐射剂量的1.8%与1.1%,手术本身辐射量有限。
- 优选随访方案下70岁男性终生归因癌症风险0.8%(1/131),30岁女性3.4%(1/29)。
核心结论
- 对于接受PCA及消融后随访成像的SRM患者,辐射剂量及相关二次癌症风险较高,尤其在年轻患者中。
- PCA操作本身的辐射暴露仅占总辐射量的有限部分。
- 放射科医生和临床医生必须努力实施辐射剂量节约措施,尤其针对随访方案。
研究设计与样本
- 单机构队列研究,纳入149例在本机构因SRM接受PCA的患者。
- 基于CT剂量报告计算CT引导PCA操作及消融后随访CT的平均有效剂量。
- 应用多学科专家组的随访建议,计算PCA操作及对应最小与优选随访方案(5年 vs 10年)的CT监测项目总辐射剂量。
- 基于最新BEIR VII报告,根据累积有效剂量估算不同年龄组的终生归因癌症风险。
诊断标准与关键数值
- PCA治疗加随访CT的总剂量在最小方案为174 mSv,在优选方案为294 mSv。
- 随访CT占总有效剂量的大部分:最小方案89%,优选方案94%。
- CT透视对总辐射剂量贡献有限:最小方案1.8%,优选方案1.1%。
- 70岁男性完成优选随访方案的终生归因癌症风险为0.8%(1/131)。
- 30岁女性完成同一优选随访方案的终生归因癌症风险为3.4%(1/29)。
临床应用与阅片要点
- 放射科医生和临床医生必须努力实施辐射剂量节约措施,尤其针对随访方案。
- PCA操作本身的辐射暴露仅占总辐射量的有限部分,随访CT是主要辐射来源。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To estimate radiation dose and the associated risk of secondary cancer risk related to percutaneous cryoablation (PCA) and follow-up imaging in a cohort of patients treated for small renal masses (SRMs).
METHODS: A total of 149 patients underwent PCA for a SRM at our institution. Based on CT dose reports, we calculated the mean effective dose for a CT-guided PCA procedure and post-ablative follow-up CT. Applying follow-up recommendations by a multidisciplinary expert panel, we calculated the total radiation dose for the PCA procedure and the CT surveillance program corresponding to a minimal and preferable follow-up regime (5-year vs 10-year). Estimates of the lifetime attributable cancer risk for different age groups were calculated based on the cumulative effective dose based on the latest BEIR VII report.
RESULTS: Total dose for the PCA treatment and follow-up CTs amounted to 174 and 294 mSv for a minimal and preferable protocol, respectively. Follow-up CTs accounted for the majority of the total effective dose for the minimal and preferable protocol (89% vs 94%). CT fluoroscopy contributed only to a limited amount of the total radiation dose for the minimal and preferable protocol (1.8% vs 1.1%). A 70-year-old male undergoing PCA treatment has a lifetime attributable cancer risk of 0.8% (1 in 131) when completing the preferable follow-up protocol. The same regimen in a 30-year-old female results in a lifetime attributable risk of cancer of 3.4% (1 in 29).
CONCLUSION: Radiation dose and the associated risk of secondary cancer are high for patients with SRMs undergoing PCA and post-ablative follow-up imaging in particular in younger patients. Radiation exposure in the PCA procedure itself accounts for only a limited amount of the total radiation. Radiologists and clinicians must strive to implement radiation dose saving measures especially with respect to the follow-up regime.
引用
- Borgbjerg J, Bylling T, Andersen G, et al. CT-guided cryoablation of renal cancer: radiation burden and the associated risk of secondary cancer from procedural- and follow-up imaging. Abdom Radiol (NY). 2020. PMID: 32285178. doi:10.1007/s00261-020-02527-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。